TABLE 3.
Pharmacokinetic parameters of Rufi-NP-RXG, Rufi-NP-Susp, and Rufi-Susp in brain and plasma following in. administration at a drug dose of 1 mg/kg.
| Matrix | Pharmacokinetic parameter | Units | Treatments | ||
|---|---|---|---|---|---|
| Rufi-NP-Susp | Rufi-NP-RXG | Rufi-Susp | |||
| Plasma | AUC0→tlast | min×(µg/ml) | 145.7 ± 21.7 | 123.1 ± 10.3 | 200.75 ± 74.4 |
| Cmax | µg/mL | 0.49 ± 0.06 | 0.35 ± 0.04 | 1.16 ± 0.53 | |
| Tmax | min | 60 | 90 | 120 | |
| MRT | min | 232.9 ± 3.7 | 218.4 ± 4.9 | 147.4 ± 9.4 | |
| Brain | AUC0→tlast | min×(µg/g) | 509.3 | 512.17 | 104.28 |
| Cmax | µg/g | 1.68 ± 0.2 | 1.60 ± 0.2 | 0.79 ± 0.11 | |
| Tmax | min | 60 | 60 | 60 | |
| % DTE | 988.5 | 1177.3 | 146.8 | ||
| % DTP | 86.06 | 91.5 | 31.9 | ||
All the parameter values are expressed as mean ± SD of (n = 4) animals per treatment group. Tmax is expressed as a range or a single value wherever applicable; in the case of plasma data, mean AUC0-tlast obtained from four animals (n = 4) was used while in the case of brain data, AUC0-tlast obtained from composite sampling with four animals sacrificed at each time point was used.